World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ISRCTN
Last refreshed on: 28 August 2023
Main ID:  ISRCTN17130982
Date of registration: 25/02/2015
Prospective Registration: Yes
Primary sponsor: Ghent University
Public title: The Ghent Psychotherapy Study (GPS)
Scientific title: Differential efficacy of supportive-expressive and cognitive behavioral interventions in dependent and self-critical depressive patients: a randomised trial
Date of first enrolment: 01/10/2015
Target sample size: 104
Recruitment status: Completed
URL:  https://www.isrctn.com/ISRCTN17130982
Study type:  Interventional
Study design:  Interventional randomised parallel study (Treatment)  
Phase:  Not Applicable
Countries of recruitment
Belgium
Contacts
Name: Mattias    Desmet
Address:  Henri Dunantlaan 2 9000 Ghent Belgium
Telephone: +32 (0)9 264 63 58
Email: info.RCT@UGent.be
Affiliation: 
Name: Mattias    Desmet
Address:  Henri Dunantlaan 2 9000 Ghent Belgium
Telephone: +32 (0)9 264 63 58
Email: Mattias.Desmet@UGent.be
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria: Current inclusion criteria as of 01/10/2015:
1. Diagnosis of current major depressive disorder according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV), as assessed in the Structured Clinical Interview for DSM Disorders (SCID-I).
2. Hamilton Depression Rating Scale (HDRS) total score >14
3. Aged 18-65
4. Outpatient
5. Sufficient knowledge of the Dutch language
6. Dominance of either dependent or self-critical personality characteristics (prototype matching procedure by Werbart and Forsström: At least a score of 3/5 for one of the patterns and a minimum of 2 points difference with the score on the other personality pattern)
7. Patients on antidepressant medication can still meet inclusion criteria and can participate in the study if they are on a stable dose for at least four weeks. All medication use will be registered in detail throughout the procedure.

Previous inclusion criteria:
1. Diagnosed with major depressive disorder, according to the description in DSM-V
2. Aged >18 years old
3. Living in the Ghent region
4. Outpatient
5. Dutch speaking

Exclusion criteria: Current exclusion criteria as of 01/10/2015:
1. Manifest psychotic symptoms or bipolar disorder
2. Acute suicidal risk
3. Current substance abuse /dependence (SCID)
4. Evidence of cognitive impairment that might prevent full participation in the treatments
5. Evidence of serious physical illness that strongly affects the depression or is causal for the depression
6. Other ongoing psychotherapeutic treatments

Previous exclusion criteria:
1. Acute psychotic episode
2. Acute suicidal tendency
3. Manifest substance abuse


Age minimum:
Age maximum:
Gender: Both
Health Condition(s) or Problem(s) studied
Major depressive disorder, conform criteria in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
Mental and Behavioural Disorders
Major depressive disorder
Intervention(s)
Current interventions as of 01/10/2015:
Patients will be randomly assigned to one of two treatments:
1. Manual-based cognitive-behavioral treatment condition (CBT)
2. Manual-based short term psychodynamic treatment condition (SET)

The CBT condition uses the Protocolled Treatment for Adults with Depressive Disorder by Bockting and Huibers (2011) that is based on the Cognitive Behavioral Treatment protocol by Beck et al. (1979). The SET condition uses the Unified Protocol by Leichsenring and Schauenburg (2014) that is based on the manual for Supportive Expressive Time Limited Therapy by Luborsky. In both condition, patients will receive 16-20 sessions of treatment, with each treatment lasting 45 minutes. Therapists with a post-graduate training and comparable clinical experience in one of both treatment types, received two days of training in the respective treatment manuals. All therapists regularly attend supervision sessions. Adherence to the treatment manuals will be checked by the provided treatment fidelity checklists.

Previous interventions:
Patients will be randomly assigned to one of two treatments:
1. Manual-based time-fixed directive treatment condition (CBT)
2. Manual-based time-fixed explorative condition (SET)

All patients will receive 20 sessions of treatment, with each treatment lasting 45 minutes. All therapists have 4 to 8 years experienced in one of both treatment types, had a post-graduate training in the given approach, and receive a one-day training in the respective treatment manuals. All therapists regularly attend supervision sessions, offered by therapists with at least 10 years of experience.
Primary Outcome(s)
Current primary outcome measures as of 01/10/2015:
Baseline and post-treatment severity of depression symptoms is derived by the Dutch version of the Hamilton Rating Scale for Depression (HDRS). Two external raters are trained to reach adequate interrater-reliability. The raters are blind to the research hypotheses, the research design, and the conditions to which the patients were assigned. The HDRS is rated on semi-structured pre- and post interviews (adjusted SCID-I for baseline severity and HDRS interview for post-treatment severity; see above and below) that are rated in random order, in order to avoid expectancy biases.

Previous primary outcome measures:
The Beck Depression Inventory-II, Dutch version (BDI-II-NL) is a symptom-specific questionnaire with 21 self-rated items, which indicates the severity of symptom of Major Depressive Disorder. It will be administered pre-treatment and post-treatment, at sessions 4, 8, 12, and 16 during treatment, and at 3-month, 6-month, 12-month and 24-month follow-up.
Secondary Outcome(s)
Current secondary outcome measures as of 01/10/2015:
1. The Beck Depression Inventory-II, Dutch version (BDI-II-NL) is a symptom-specific questionnaire with 21 self-rated items, which indicates the severity of symptoms of Major Depressive Disorder. It will be administered pre-treatment and post-treatment, at sessions 4, 8, 12, and 16 during treatment, and at 3-month, 6-month, 12-month and 24-month follow-up.
2. The Inventory of Interpersonal Problems-32 (IIP-32) is a self-rated questionnaire with 32 items that indicates the most salient interpersonal problems. It is administered pre-treatment and posttreatment, at sessions 4, 8, 12, and 16 during treatment, and at 3-month, 6-month, 12-month and 24-month follow-up.
3. The Symptom Checklist-90-Revised (SCL-90-R) is a self-rated questionnaire with 90 items that indicates a range of psychopathology symptoms. It is administered pre-treatment and post-treatment, at sessions 4, 8, 12, and 16 during treatment, and at 3-month, 6-month, 12-month and 24-month follow-up.
4. Outcome Questionnaire-45 (OQ-45) is a self-rated questionnaire with 45 items that indicates general wellbeing. It is administered pre-treatment and post-treatment, at sessions 4, 8, 12, and 16 during treatment, and at 3-month, 6-month, 12-month and 24-month follow-up.
5. The shortened Depression Anxiety and Stress Scale (DASS) is a 21-item self-report questionnaire on the presence and severity of symptoms of depression, anxiety and stress. It is administered pretreatment and post-treatment, at every session of the treatment process, and at 3-month, 6-month, 12-month and 24-month follow-up.
6. Cortisol stress levels are analyzed as indicators of stress, by means of mass spectrometry of saliva and hair samples. The saliva samples are gathered for four consecutive days (one sample early morning and one late evening every day) at pre-treatment and post-treatment, at sessions 4, 8, 12, and 16 during treatment, and at 3-month, 6-month, 12-month and 24-month follow-up. The hair-samples are gathered at pre-treatment, peri-treatment and post-treatment and at 6-month and 24-month follow-up.
7. Cost-efficiency by means of health-care cost information is retrieved via the Inter-mutualistic Agency (http://www.nic-ima.be), covering a period starting 3 years pretreatment until 2 years post-treatment. This is one of the only ways to gather objective information on a longer period before the patient enters therapy; and it can be used to get a clear picture of antidepressant medication use.

Process Measures / Clinical Predictors
1. The Client Change Interview (CCI) is a semi-structured interview focused at patient experience of the process of change during and following the treatment process. It is administered around the 12th treatment session, at post treatment and at 6-month and 24-month follow-up.
2. An idiosyncratic complaint is formulated at the onset of treatment, and rated by the patient on a continuous scoring line (the far left end indicates absence of the complaint, the far right end indicates full presence and severe suffering from the complaint). It is rated retrospectively for the week before each treatment session.
3. Medication use changes are indicated at every treatment session.
4. The Emotion Checklist is a visual analogous scale (VAS) with ten scales on which the current emotional state is rated before every treatment session.
5. The Working Alliance Inventory (WAI) is a 12-item questionnaire focused on the working alliance between the therapist and the patient as experienced during the treatment session. The questionnaire is completed every 4th session by both the patient and the therapist.
6. The Core Conflictual Relationship Theme (CCRT) is a rating scale instrument that indicates interactional patterns in treatment processes, which is used to study recurrent relationship patterns coming forth from the transcripts. Two independent raters, blind with respect to the research design, are trained to do the CCRT ratings. All treatment sessions are audiotaped and (partly) transcribed for the purpose of such qualitative analyses.
7. Biomarkers and epigenetics are analyzed by means of mass spectrometry of blood samples that are gathered at pre-treatment and post-treatment.
8. The Shortened Character-Temperament questionnaire (SCTI) is a personality questionnaire with 104 self-rated items, which assesses character and temperament profiles. It will be administered pre- and post-treament.
9. The Experiences in Close Relationships, Dutch version (ECR) is a self-report questionnaire with 36 items to assess adult attachment style. It will be administered pre-treatment and post-treatment.
10. The Zelfinventarisatievragenlijst Posttraumatische Stoornis (ZIL) is a symptom-specific questionnaire with 22 self-rated items, which assesses the presence of posttraumatic stress disorder symptoms. It will be administered pre-treatment, peri-treatment (at session 8) and post-treatment, and at 12-month follow-up.
11. The VAS for Countertransference is a visual analogue scale that inquires countertransference by the therapist. It consists of 7 subscales for countertransference and is completed by the therapist after treatment sessions 1-3, 5-7, 9-11, 13-15 and 17 -19.
12. The Therapist Response Questionnaire, Dutch version (TRQ) is a 79-item self-report questionnaire which measures countertransference in the therapist. It is completed by the therapist after sessions 4, 8, 12, 16 and 20.

Screening materials?
1. The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental (DSM) Disorders (SCID-I) is used to screen potential participants before the treatment process. If patients meet the criteria for major depressive disorder, additional screening is done, starting with the administration of the SCID-II to exclude patients with manifest substance abuse, acute psychotic symptoms and/or suicidal ideations, and to detect comorbidity. After treatment, the SCID-I and SCID-II are administered again to indicate changes in psychopathology.
2. The Clinical Diagnostic Interview (CDI), a semi-structured interview that assesses DSM-IV-TR Axis I and II symptoms narratively, is administered to indicate comorbidity and severity of symptoms from the patient’s experience.
3. Personality styles or potential participants are identified by the rating of transcribed CDIs, using clinical vignettes provided by Werbart and Forsström (2014). These vignettes includes a list of typical needs, concerns, relational attitudes, and coping mechanisms of both dependency and self-criticism, all rated on a 5 point rating scale ranging from ‘little or no match’ to ‘very good match (prototypical case)’. Inter-rater reliabilities observed with this procedure are adequately high (ranging between .85 and .95). A team of postgraduate research assistants is trained until adequate inter-rater reliability with an expert rater is reached. Inter-rater reliabilities observed with this procedure are adequately high (ranging between 0.85 and 0.95).?Prototype matching for each patient is conducted in supervised cartel discussions.
4. The personality styles identified by ratings, are validated by administration of the self-rating questionnaires the Personality Style Inventory (PSI) and the Depressive Experiences Questionnaire (DEQ). The PSI distinguishes between the dependent and the self-critical personality style. The DEQ distinguishes between the sociotropic and autonomous personality styles, which resemble the dependent and the self-critical personality style, respectively.
A number of materials such as the SCID, the CDI and the BDI-II-NL are based on the diagnostic typology described in DSM-IV-TR. As the DSM-IV-TR was recently replaced by DSM-V, but no (Dutch translations of) updated versions of the measures are available yet, in this study the current measures are still used. Nonetheless, we compa
Secondary ID(s)
N/A
Source(s) of Monetary Support
Universiteit Gent
Secondary Sponsor(s)
Ethics review
Status:
Approval date:
Contact:
Old ethics approval format; Commissie Medische Ethiek of the Universitair Ziekenhuis Gent (Ghent University Hospital), 05/05/2015 An amendment was granted for changes in the design on 23/09/2015, ref: 2015/0085
Results
Results available: Yes
Date Posted:
Date Completed: 31/12/2019
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history